Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 40

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 40
---
 2024. (2) The amounts reported in this column represent the aggregate grant date fair value of the stock options granted to our named executive officers during the relevant years, computed in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. The assumptions used in calculating the grant date fair value of the stock options reported in this column for 2024 are set forth in Note 2 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. (3) The amounts reported in this column for 2024 for Ms. Davis and Dr. Nistala represent employer matching contributions to their respective 401(k) plan or UK workplace pension scheme during the

23

TABLE OF CONTENTS

year ending December 31, 2024. For Dr. Sidhu, the amounts reported in this column for 2024 reflect (a) compensation received by him in connection with the CEO Transition pursuant to the terms of his settlement agreement with the Company, as described below in the narrative to this Summary Compensation Table under the heading “Potential Payments Upon Termination or Change in Control,” which includes (i) a $140,760 cash payment in lieu of the notice required under his employment agreement with the Company, (ii) a $140,760 cash payment as compensation in connection with the CEO Transition, and (iii) a $281,520 cash severance payment; (b) a $14,490 cash payment as reimbursement for tax advice in connection with entering into the settlement agreement; and (c) fees paid to Dr. Sidhu for his service as a non-employee director following the CEO Transition in April 2024, which include (i) a $34,526 cash retainer and (ii) $251,082, which is the grant date fair value of the stock options granted to him for such service as a non-employee director, computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of Dr. Sidhu’s non-employee director stock option reported in this column for 2024 are set forth in Note 2 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. (4) Mr. Lisicki joined the Company as President and Chief Operating Officer, effective January 8, 2024. Effective April 8,